N-terminal pro-B-type natriuretic peptide level inversely associates with metabolic syndrome in elderly persons

Diabetology & Metabolic Syndrome

Bang-Gee Hsu²  Yu-Chih Chen³  Jen-Che Hsieh³  Chung-Jen Lee¹  Ji-Hung Wang³ 

[1] Department of Nursing, Tzu Chi College of Technology, Hualien, Taiwan;Division of Nephrology, Buddhist Tzu Chi General Hospital, No. 707, Section 3, Chung-Yang Road, Hualien, Taiwan;Division of Cardiology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan

关键词: Metabolic syndrome;    Elderly;    N-terminal pro-B-type natriuretic peptide;   

Others  :  805399
DOI  :  10.1186/1758-5996-6-15

 received in 2013-09-29, accepted in 2014-02-05,  发布年份 2014

【 摘 要 】

Aims

Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) was lower in the general population with metabolic syndrome (MetS). The aim of this study was to evaluate the relationship between MetS and fasting serum NT-proBNP concentration in elderly persons.

Methods

Fasting blood samples were obtained from 84 elderly volunteers aged 65 years or older. MetS and its components were defined using diagnostic criteria from the International Diabetes Federation.

Results

Thirty-eight elderly persons (45.2%) had MetS. Fasting NT-proBNP level was negatively correlated with MetS among elderly patients (p = 0.001). Univariate linear regression analysis showed that age (r = 0.338; p = 0.002) was positively correlated with fasting serum log-NT-proBNP levels, while height (r = -0.253; p = 0.020), body weight (r = -0.238; p = 0.029), waist circumference (r = -0.270; p = 0.013), body fat mass (r = -0.356; p = 0.002) and triglyceride (r = -0.291; p = 0.007) were negatively correlated with fasting serum log-NT-proBNP levels among the elderly persons. Multivariate forward stepwise linear regression analysis of the significant variables showed that age (R² change = 0.114, p = 0.011), triglyceride (R² change = 0.118, p < 0.001), body fat mass (R² change = 0.084, p < 0.001), and height (R² change = 0.101, p < 0.001) were the independent predictor of fasting serum log-NT-proBNP levels in elderly persons.

Conclusions

NT-proBNP level is significantly reduced in elderly persons affected by MetS, and is significantly positively related to age, while negatively related to triglyceride, body fat mass, height in these subjects.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Potter LR: Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011, 278:1808-1817.
• [2]Clerico A, Recchia FA, Passino C, Emdin M: Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006, 290:H17-H29.
• [3]Gopal DJ, Iqbal MN, Maisel A: Updating the role of natriuretic peptide levels in cardiovascular disease. Postgrad Med 2011, 123:102-113.
• [4]Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A: Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008, 26:831-843.
• [5]Beleigoli AM, Diniz MF, Ribeiro AL: Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions: a systematic review. Obes Rev 2009, 10:617-626.
• [6]Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al.: N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005, 46:660-666.
• [7]Bao Y, Shang X, Zhou L, Hu R, Li Y, Ding W: Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci 2011, 7:247-256.
• [8]Sepe A, Tchkonia T, Thomou T, Zamboni M, Kirkland JL: Aging and regional differences in fat cell progenitors - a mini-review. Gerontology 2011, 57:66-75.
• [9]Sun DL, Wang JH, Jiang B, Li LS, Li LS, Wu L, et al.: Metabolic syndrome vs. its components for prediction of cardiovascular mortality: a cohort study in Chinese elderly adults. J Geriatr Cardiol 2012, 9:123-129.
• [10]Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al.: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
• [11]Hsieh JC, Wang JH, Lee CJ, Chen YC, Liou HH, Hsu BG: Low serum long-acting natriuretic peptide level correlates with metabolic syndrome in hypertensive patients: a cross-sectional study. Arch Med Res 2013, 44:215-220.
• [12]Wang JH, Lee CJ, Hsieh JC, Chen YC, Hsu BG: Inversely association of long-acting natriuretic peptide with metabolic syndrome in congestive heart failure patients. Diabetol Metab Syndr 2013, 5:19. BioMed Central Full Text
• [13]Quinones MA, Waggoner AD, Reduto LA, Nelson JG, Young JB, Winters WL Jr, et al.: A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981, 64:744-753.
• [14]Aizawa Y, Sakata Y, Mano T, Takeda Y, Ohtani T, Tamaki S, et al.: Transition from asymptomatic diastolic dysfunction to heart failure with preserved ejection fraction – roles of systolic function and ventricular distensibility. Circ J 2011, 75:596-602.
• [15]Alberti KG, Zimmet PZ, Shaw J: Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
• [16]Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
• [17]Lakatta EG, Levy D: Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation 2003, 107:139-146.
• [18]Sinclair A, Viljoen A: The metabolic syndrome in older persons. Clin Geriatr Med 2010, 26:261-274.
• [19]Noale M, Maggi S, Zanoni S, Limongi F, Zambon S, Crepaldi G, ILSA working group: The metabolic syndrome, incidence of diabetes and mortality among the elderly: the Italian Longitudinal Study of Ageing. Diabetes Metab 2012, 38:135-141.
• [20]Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
• [21]Savoia C, Volpe M, Alonzo A, Rossi C, Rubattu S: Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci 2009, 118:231-240.
• [22]Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, et al.: Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009, 58:2880-2892.
• [23]Sezen Y, Baş M, Demirbag R, Yildiz A, Celik H, Aksoy S: N-terminal pro-brain natriuretic peptide in cases with metabolic syndrome and its relationship with components of metabolic syndrome and left ventricular mass index. Clin Biochem 2009, 42:1500-1503.
• [24]Li WY, Chiu FC, Chien YF, Lin JW, Hwang JJ: Association of amino-terminal pro-brain natriuretic peptide with metabolic syndrome. Intern Med 2011, 50:1143-1147.
• [25]Nadrowski P, Chudek J, Grodzicki T, Mossakowska M, Skrzypek M, Wiecek A, et al.: Plasma level of N-terminal pro brain natriuretic peptide (NT-proBNP) in elderly population in Poland - The PolSenior Study. Exp Gerontol 2013, 48:852-857.
• [26]Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, et al.: Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 2011, 108:1341-1345.
• [27]Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al.: Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002, 90:254-258.
• [28]Taçoy G, Açikgöz K, Kocaman SA, Ozdemir M, Cengel A: Is there a relationship between obesity, heart rate variability and inflammatory parameters in heart failure? J Cardiovasc Med 2010, 11:118-124.
• [29]Cheng S, Fox CS, Larson MG, Massaro JM, McCabe EL, Khan AM, et al.: Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol 2011, 108:979-984.
• [30]Muscari A, Berzigotti A, Bianchi G, Giannoni C, Ligabue A, Magalotti D, et al.: Non-cardiac determinants of NT-proBNP levels in the elderly: relevance of haematocrit and hepatic steatosis. Eur J Heart Fail 2006, 8:468-476.
• [31]Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al.: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107:1278-1283.
• [32]Marinsek M, Sinkovic A: A randomized trial comparing the effect of ramipril and losartan in survivors of ST-elevation myocardial infarction. J Int Med Res 2009, 37:1577-1587.
• [33]Rosenberg J, Gustafsson F, Remme WJ, Riegger GA, Hildebrandt PR: Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther 2008, 22:305-311.
• [34]Stypmann J, Schubert A, Welp H, Schulte H, Assmann G, Breithardt G, et al.: Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Clin Cardiol 2008, 31:478-481.
• [35]Muscari A, Bianchi G, Forti P, Giansante C, Giovagnoli M, Magalotti D, et al.: A comparison of risk factors as predictors of cardiovascular and non-cardiovascular mortality in the elderly people–relevance of N-terminal pro-B-type natriuretic peptide and low systolic blood pressure. Int J Clin Pract 2013, 67:1182-1191.
• [36]Golcuk Y, Golcuk B, Velibey Y, Oray D, Atilla OD, Colak A, et al.: Predictive cutoff point of admission N-terminal pro-B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure. Am J Emerg Med 2013, 31:1191-1195.
• [37]Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, et al.: Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009, 53:2070-2077.
• [38]Hung J, McQuillan BM, Thompson PL, Beilby JP: Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes 2008, 32:772-779.
• [39]Sung SH, Chuang SY, Sheu WH, Lee WJ, Chou P, Chen CH: Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal pro-B-type natriuretic peptide in the general population. Am J Cardiol 2009, 103:1411-1416.
• [40]Baldasseroni S, Mannucci E, Orso F, Di Serio C, Pratesi A, Bartoli N, et al.: Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure. Nutr Metab Cardiovasc Dis 2012, 22:292-299.